In addition, PD-L1 is downstream of BRD4, and BRD4 inhibition facilitates the anti-tumor immune response in cancer patients by suppressing PD-L1 expression (Zhu et al., 2016; Hogg et al., 2017). Here, BRD4 is linked to cancer.